We provide you with 20 years of free, institutional-grade data for SRRA stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of SRRA. Explore the full financial landscape of SRRA stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Turner William D. | Sale | -6,447 | $37.09 | $239,119 | 2022-04-07 |
| Turner William D. | Derivatives Exercise | 6,447 | 2022-04-07 | ||
| Thomson Mary Christina | Sale | -2,000 | $35.14 | $70,277 | 2022-04-04 |
| Thomson Mary Christina | Derivatives Exercise | 2,000 | 2022-04-04 | ||
| Turner William D. | Sale | -100 | $37.05 | $3,705 | 2022-03-22 |
| Turner William D. | Derivatives Exercise | 100 | 2022-03-22 | ||
| Turner William D. | Sale | -3,453 | $37.06 | $127,954 | 2022-03-17 |
| Turner William D. | Derivatives Exercise | 3,453 | 2022-03-17 | ||
| Thomson Mary Christina | Sale | -2,000 | $30.6 | $61,196 | 2022-03-04 |
| Thomson Mary Christina | Derivatives Exercise | 2,000 | 2022-03-04 | ||
| Turner William D. | Sale | -10,000 | $32.32 | $323,225 | 2022-02-08 |
| Turner William D. | Derivatives Exercise | 10,000 | 2022-02-08 | ||
| Thomson Mary Christina | Sale | -2,000 | $29.78 | $59,560 | 2022-02-04 |
| Thomson Mary Christina | Derivatives Exercise | 2,000 | 2022-02-04 | ||
| Longitude Capital Partners III, LLC | Open Market Purchase | 175,000 | $27 | 2022-02-02 | |
| Richardson Joshua | Open Market Purchase | 175,000 | $27 | 2022-02-02 | |
| Sinclair Andrew | Open Market Purchase | 150,000 | $27 | 2022-02-01 | |
| Abingworth LLP | Open Market Purchase | 150,000 | $27 | 2022-02-01 | |
| Aggarwal Gaurav | Open Market Purchase | 800,000 | $27 | 2022-01-31 | |
| Vivo Opportunity, LLC | Open Market Purchase | 800,000 | $27 | 2022-01-31 | |
| Thomson Mary Christina | Sale | -2,000 | $29 | $58,000 | 2022-01-28 |
| Thomson Mary Christina | Derivatives Exercise | 2,000 | 2022-01-28 | ||
| Turner William D. | Sale | -5,000 | $27.05 | $135,250 | 2022-01-28 |
| Turner William D. | Derivatives Exercise | 5,000 | 2022-01-28 | ||
| Collard Craig A | Open Market Purchase | 13,500 | $22.95 | 2021-11-24 | |
| DILLY STEPHEN GEORGE | Open Market Purchase | 5,000 | $17.83 | 2021-05-20 | |
| Klencke Barbara | Open Market Purchase | 3,325 | $12.25 | 2020-08-18 | |
| Klencke Barbara | Open Market Purchase | 5,950 | $12.22 | 2020-08-18 |
The information provided in this report about SRRA stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Sierra Oncology, Inc(NASDAQ:SRRA) 
Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatm...
Website: http://www.sierraoncology.com
Founded: 2003
Full Time Employees: 69 (May 2021)
Sector: Healthcare
Industry: Biotechnology